Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05240976 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. 3 versions Re-verified since Aug 6, 2023, no change to tracked fieldsv3-v5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2022 to Feb 23, 2022
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Previous study found that some NMDA-enhancing agent was able to augment efficacy of clozapine for clinical symptoms but not cognitive function in the treatment of ultra-resistant schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia. Whether a drug with anti-inflammatory property can strengthen the efficacy of an NMDA-enhancer (NMDAE) in the treatment of ultra-resistant schizophrenia remains unknown.
Trial Details
NCT Number NCT05240976
Lead Sponsor China Medical University Hospital
Collaborators: National Health Research Institutes, Taiwan
Conditions
(from sponsor)		 Schizophrenia
Related terms Inflammation, Schizophrenia
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov